This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sato, E I Search for Related Content PubMed PubMed Citation Articles by Sato, E I Social Bookmarking                   What's this?

Methotrexate therapy in systemic lupus erythematosus

Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil; Rua Botucatu 740, Disciplina de Reumatologia — UNIFESP, CEP 04023900,São Paulo, Brazil emiliasato{at}reumato.epm.br

There are 12 non-controlled and only two controlled studies using methotrexate (MTX) in a total of 207 SLE patients in the literature. The majority of these studies evaluated mainly cutaneous and/or articular involvement and attained good results. Two studies evaluated a small number ofpatients with lupus nephritis, achieving discordant results. Two other studies in pediatric onset systemic lupus erythematosus (SLE) also presented conflicting results, it being relevant that the one with poor response hadthe majority of patients with nephritis. One of the controlled trials was retrospective and concluded that MTX was effective in the treatment of antimalarial-resistant lupus arthritis and that toxicity leading to discontinuation of MTX was infrequent. The other controlled study was a double-blind, randomized, placebo-controlled clinical trial that evaluated SLE patients with mild activity. The authors concluded that MTX was effective in controlling cutaneous and articular activity and permitted prednisone dose reduction. The side effects were frequent but only 10% of patients needed to discontinue the medication.

The accumulative evidence suggests that MTX in a low weekly dose may be effective in SLE patients with articular and/or cutaneous involvement with no response to antimalarials and low-dose prednisone and in patients in whom we can not reduce prednisone dose due to articular or cutaneous activity. Caution is required concerning the side effects.

Key Words: methotrexate • systemic lupus erythematosus • therapy

Lupus, Vol. 10, No. 3, 162-164 (2001)
DOI: 10.1191/096120301666080831


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B Ostendorf, C Iking-Konert, K Kurz, G Jung, O Sander, and M Schneider Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis Ann Rheum Dis, April 1, 2005; 64(4): 630 - 633. [Abstract] [Full Text] [PDF]

				J M Wong and J M Esdaile Methotrexate in systemic lupus erythematosus Lupus, February 1, 2005; 14(2): 101 - 105. [Abstract] [PDF]

				G Malcangi, G Brandozzi, M Giangiacomi, M Zampetti, and M G Danieli Bullous SLE: response to methotrexate and relationship with disease activity Lupus, January 1, 2003; 12(1): 63 - 66. [Abstract] [PDF]